Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States.
BMC Pulm Med
; 22(1): 18, 2022 Jan 10.
Article
en En
| MEDLINE
| ID: mdl-35000589
ABSTRACT
BACKGROUND:
The anti-fibrotic medications nintedanib and pirfenidone were approved in the United States for use in patients with idiopathic pulmonary fibrosis several years ago. While there is a growing body of evidence surrounding their clinical effectiveness, these medications are quite expensive and no prior cost-effectiveness analysis has been performed in the United States.METHODS:
A previously published Markov model performed in the United Kingdom was replicated using United States data to project the lifetime costs and health benefits of treating idiopathic pulmonary fibrosis with (1) symptom management; (2) pirfenidone; or (3) nintedanib. For the cost-effectiveness analysis, strategies were ranked by increasing costs and then checked for dominating treatment strategies. Then an incremental cost-effectiveness ratio was calculated for the dominant therapy.RESULTS:
The anti-fibrotic medications were found to cost more than $110,000 per year compared to $12,291 annually for symptom management. While pirfenidone was slightly more expensive than nintedanib and provided the same amount of benefit, neither medication was found to be cost-effective in this U.S.-based analysis, with an average cost of $1.6 million to gain one additional quality-adjusted life year over symptom management.CONCLUSIONS:
Though the anti-fibrotics remain the only effective treatment option for patients with idiopathic pulmonary fibrosis and the data surrounding their clinical effectiveness continues to grow, they are not considered cost-effective treatment strategies in the United States due to their high price.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Piridonas
/
Fibrosis Pulmonar Idiopática
/
Antifibróticos
/
Indoles
Tipo de estudio:
Health_economic_evaluation
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
BMC Pulm Med
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos